首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Granulocyte Colony Stimulating Factor for Prevention of?Craniospinal Radiation Treatment Interruption among Central?Nervous System Tumor Patients
【24h】

Granulocyte Colony Stimulating Factor for Prevention of?Craniospinal Radiation Treatment Interruption among Central?Nervous System Tumor Patients

机译:粒细胞集落刺激因子预防中枢神经系统肿瘤患者颅骨放射治疗中断

获取原文
           

摘要

Objectives: In this pilot randomized clinical trial the preventive effects of weekly granulocyte colonystimulating factor (GCSF) injection for patients with central nervous system (CNS) tumors receiving craniospinalirradiation were assessed with regard to risk of treatment interruption. Methods: We randomized 40 CNS cancerpatients into two groups (20 patients each), the first receiving GCSF prevention therapy before weekly craniospinalradiotherapy and the control group without this prophylaxis. The main outcome was whether GCSF preventivetherapy decreased the rate of interruption of radiotherapy because of leucopenia and thrombocytopenia. Weused t -test, and chi-square test statistics to compare the quantitative and qualitative outcomes. Results: therewere no significant differences in platelets and WBC loss between the treatment and control groups. Treatmentinterruption was lower in weekly GCSF therapy group (35%), compared to the control group (55%), althoughthe difference was not statistically significant (P value 0.2). While 8 patients (40%) also received GCSF therapydue to leucopenia in the control group only one patient reached a critical level and needed GCSF therapy becauseof irradiation complications (p-value 0.02). Among those who received naodjuvant chemotherapy (8 patientsin each group), among the GCSF prevention group only in one (12%) we had to interrupt radiotherapy, ascompared to 6 in the control group due to WBC loss. Conclusion: Weekly GSCF injections among CNS tumorpatients receiving craniospinal therapy may decrease treatment interruption. A larger study with longer followupis now needed to confirm our results.
机译:目的:在该试验性随机临床试验中,评估了每周一次粒细胞集落刺激因子(GCSF)注射液对接受颅脑脊髓放射治疗的中枢神经系统(CNS)肿瘤患者的预防效果。方法:我们将40名中枢神经系统癌症患者随机分为两组(每组20名患者),第一组在每周进行颅脑脊髓放射治疗之前接受GCSF预防治疗,而对照组则没有这种预防措施。主要结果是GCSF预防疗法是否由于白细胞减少症和血小板减少症而降低了放疗的中断率。我们使用t检验和卡方检验统计量来比较定量和定性结果。结果:治疗组和对照组之间的血小板和白细胞损失没有显着差异。每周GCSF治疗组(35%)的治疗中断率低于对照组(55%),尽管差异无统计学意义(P值0.2)。对照组中有8位患者(40%)由于白细胞减少症也接受了GCSF治疗,只有一名患者由于放射并发症而达到临界水平并需要进行GCSF治疗(p值0.02)。在接受naodjuvant化疗的患者(每组8例)中,在GCSF预防组中,只有一例(12%)中我们不得不中断放疗,而对照组中由于白细胞减少而有6例。结论:在接受颅脊柱治疗的中枢神经系统肿瘤患者中每周GSCF注射可以减少治疗中断。现在需要进行更大范围的随访,以证实我们的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号